期刊
BRITISH JOURNAL OF DERMATOLOGY
卷 179, 期 1, 页码 16-29出版社
WILEY
DOI: 10.1111/bjd.16239
关键词
-
类别
资金
- Novartis Pharmaceuticals Corporation
Patients with psoriasis are at an increased risk for nonalcoholic fatty liver disease (NAFLD) compared with the general population. However, the pathophysiology underlying this comorbidity and elucidation of effective treatment strategies are unclear. This review provides insights into the possible role of chronic, low-grade inflammation in the pathogenesis of NAFLD in patients with psoriasis. Both conditions are associated with increased levels of proinflammatory adipokines (such as tumour necrosis factor-a and interleukin-6) and hepatokines, and decreased levels of adiponectin, an anti-inflammatory adipokine. This imbalance in inflammatory mediators could result in insulin resistance and, thereby, facilitate the occurrence and progression of NAFLD in a multistep manner. All patients with psoriasis should, therefore, be considered candidates for NAFLD screening and managed accordingly. Given the common aetiology of inflammation between these conditions, it is hypothesized that biological therapies for psoriasis may attenuate the systemic inflammatory process and progression of NAFLD in patients with psoriasis. What's already known about this topic? Patients with psoriasis have an increased risk of nonalcoholic fatty liver disease and increased levels of proinflammatory adipokines and hepatokines. What does this study add? This article explores the possible role of chronic, low-grade inflammation in the pathogenesis of nonalcoholic fatty liver disease. All patients with psoriasis should be screened for nonalcoholic fatty liver disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据